JP Morgan Chase’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

JP Morgan Chase’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$840K	–	7530
2025 Q2	$840K	Hold	30,000	–	–	﹤0.01%	4491
2025 Q1	$754K	Buy	+30,000	New	+$758K	﹤0.01%	4530
2023 Q1	–	Sell	-23,800	Closed	-$1.06M	–	6905
2022 Q4	$1.06M	Buy	+23,800	New	+$1M	﹤0.01%	4000
2022 Q3	–	Sell	-11,900	Closed	-$664K	–	6598
2022 Q2	$664K	Buy	+11,900	New	+$706K	﹤0.01%	4376

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase's LKFT Position: Q2 2026 in Review

JP Morgan Chase increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 780% in Q2 2026, buying an estimated $33.2K and bringing the position to 1,320 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6519.

JP Morgan Chase first reported a position in LKFT in Q3 2017 and has held it in 32 quarters since. The position peaked at $18.6M in Q1 2022. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

JP Morgan Chase held 1,320 shares of Lakefront Biotherapeutics American Depositary Shares worth $39.2K as of Q2 2026.
JP Morgan Chase bought 1,170 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $33.2K.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6519 holding.
JP Morgan Chase first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2017 and has held it in 32 quarters since.
JP Morgan Chase's Lakefront Biotherapeutics American Depositary Shares position peaked at $18.6M in Q1 2022.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.